Enorama Pharma AB (ERMA) - Cash Flow Conversion Efficiency

Latest as of March 2026: 0.330x

Based on the latest financial reports, Enorama Pharma AB (ERMA) has a cash flow conversion efficiency ratio of 0.330x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-12.09 Million ≈ $-1.30 Million USD) by net assets (Skr-36.63 Million ≈ $-3.94 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Enorama Pharma AB liquidity coverage in days to measure how many days the company can operate on defensive assets alone.

Enorama Pharma AB - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Enorama Pharma AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Enorama Pharma AB Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Enorama Pharma AB ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Elevai Labs, Inc. Common Stock NASDAQ:ELAB	-0.223x
Fuller Smith & Turner LSE:FSTA	0.093x
Card Factory PLC LSE:CARD	0.063x
Vault Strategic Mining Corp. V:KNOX	0.054x
Aino Health AB ST:AINO	0.211x
Omega Therapeutics Inc NASDAQ:OMGA	-1.214x
Calidi Biotherapeutics Inc. NYSE MKT:CLDI	-1.342x
Zotefoams PLC LSE:ZTF	0.169x

Annual Cash Flow Conversion Efficiency for Enorama Pharma AB (2014–2025)

The table below shows the annual cash flow conversion efficiency of Enorama Pharma AB from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Enorama Pharma AB (ERMA) market capitalisation.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	Skr-23.45 Million ≈ $-2.52 Million	Skr-59.26 Million ≈ $-6.38 Million	2.527x	+155.23%
2024-12-31	Skr7.80 Million ≈ $839.73K	Skr-35.70 Million ≈ $-3.84 Million	-4.575x	-116.20%
2023-12-31	Skr19.54 Million ≈ $2.10 Million	Skr-41.35 Million ≈ $-4.45 Million	-2.116x	-102.43%
2022-12-31	Skr31.52 Million ≈ $3.39 Million	Skr-32.96 Million ≈ $-3.55 Million	-1.045x	+25.99%
2021-12-31	Skr21.35 Million ≈ $2.30 Million	Skr-30.16 Million ≈ $-3.25 Million	-1.413x	+89.09%
2020-12-31	Skr1.78 Million ≈ $191.23K	Skr-23.00 Million ≈ $-2.47 Million	-12.942x	-249.80%
2019-12-31	Skr7.18 Million ≈ $772.64K	Skr-26.56 Million ≈ $-2.86 Million	-3.700x	-371.31%
2018-12-31	Skr17.02 Million ≈ $1.83 Million	Skr-13.36 Million ≈ $-1.44 Million	-0.785x	+13.32%
2017-12-31	Skr7.36 Million ≈ $792.18K	Skr-6.67 Million ≈ $-717.43K	-0.906x	-34.48%
2016-12-31	Skr9.08 Million ≈ $977.10K	Skr-6.11 Million ≈ $-658.02K	-0.673x	-1015.31%
2015-12-31	Skr6.52 Million ≈ $702.09K	Skr480.00K ≈ $51.66K	0.074x	-36.25%
2014-12-31	Skr2.66 Million ≈ $286.26K	Skr307.00K ≈ $33.04K	0.115x	--

About Enorama Pharma AB

ST:ERMA Sweden Drug Manufacturers - Specialty & Generic

Market Cap

$2.69 Million

Skr24.99 Million SEK

Market Cap Rank

#29609 Global

#678 in Sweden

Share Price

Skr0.34

Change (1 day)

-3.46%

52-Week Range

Skr0.27 - Skr3.00

All Time High

Skr170.21